{"id":146774,"date":"2026-04-28T13:30:01","date_gmt":"2026-04-28T17:30:01","guid":{"rendered":"https:\/\/medcitynews.com\/?p=146774"},"modified":"2026-04-29T10:09:09","modified_gmt":"2026-04-29T14:09:09","slug":"immunology-inflammation-startup-coultreon-biopharma-sik-inhibitor-galapagos","status":"publish","type":"post","link":"https:\/\/medcitynews.com\/2026\/04\/immunology-inflammation-startup-coultreon-biopharma-sik-inhibitor-galapagos\/","title":{"rendered":"Immunology-Focused Coultreon Adds $125M for Pills That Pack the Punch of Injectable Biologics"},"content":{"rendered":"<p>Biopharmaceutical companies continue to hunt for new immunology drugs that bring patients the same benefit as injectable antibody medicines, but in the form of more convenient daily pills. Coultreon Biopharma has more fuel for this chase from <a href=\"https:\/\/www.globenewswire.com\/news-release\/2026\/04\/28\/3282440\/0\/en\/coultreon-biopharma-raises-125-million-in-series-a-financing-to-advance-immunology-pipeline.html\" target=\"_blank\" rel=\"noopener\">$125 million<\/a> that the startup will use to advance its lead program to mid-stage clinical development.<\/p>\n<p>Coultreon is the new name for Onco3R Therapeutics, a Leuven, Belgium-based startup formed last year with assets acquired from Galapagos. Onco3R aimed to develop these small molecules for autoimmune disease and cancer. As Coultreon, the new company name announced Tuesday, the startup is narrowing its focus to immunology and metabolic disease.<\/p>\n<p>Before <a href=\"https:\/\/medcitynews.com\/2025\/05\/galapagos-strategic-alternatives-spinco-cell-therapy-cancer-glpg\/\" target=\"_blank\" rel=\"noopener\">Galapagos\u2019s ill-fated foray into cancer cell therapy<\/a>, immunology was its focus. The company\u2019s search for new mechanisms of action in immunology led to a novel class of targets called <a href=\"https:\/\/journals.physiology.org\/doi\/full\/10.1152\/physrev.00023.2022\" target=\"_blank\" rel=\"noopener\">salt-inducible kinases (SIK)<\/a>, a family of enzymes that regulate immune and metabolic responses. In its <a href=\"https:\/\/www.sec.gov\/ix?doc=\/Archives\/edgar\/data\/1421876\/000155837023004448\/glpg-20221231x20f.htm\" target=\"_blank\" rel=\"noopener\">2022 annual report<\/a>, Galapagos said SIK inhibition could reduce the production of pro-inflammatory signaling proteins while also enhancing production of immunoregulatory mediators.<\/p>\n<p>\u201cThis unique mechanism-of-action offers the potential to restore the immune balance that is typically out of balance in autoimmune diseases, and differentiate product candidates from existing therapies that predominantly act by suppressing the immune system,\u201d Galapagos said in the report.<\/p>\n<p>Lead Coultreon program COL-5671 (formerly O3R-5671) is a SIK3 inhibitor that was the most advanced molecule from Galapagos\u2019s SIK research. Coultreon describes this molecule as selective to SIK3, avoiding the toxicities that can come from also hitting SIK1 and SIK2. Preclinical research showed this drug inhibited the release of two inflammatory cytokines, TNF\u03b1 and IL-23. The drug also promoted the release of the immunomodulatory cytokine IL-10.<\/p>\n<p>TNF\u03b1 inhibition is the mechanism of action of blockbuster biologic drugs such as AbbVie\u2019s Humira, Amgen\u2019s Enbrel, and Johnson &amp; Johnson\u2019s Remicade. All three products have approvals in multiple immunological indications, but each must be administered via a needle in the arm.<\/p>\n<p><a href=\"https:\/\/www.globenewswire.com\/news-release\/2026\/02\/20\/3241718\/0\/en\/O3R-5671-Pharmacokinetic-and-Pharmacodynamic-Data-to-be-Presented-at-ECCO-and-Dosing-in-Final-Cohort-in-First-in-human-study-initiated.html\" target=\"_blank\" rel=\"noopener\">Preliminary Phase 1 results<\/a> for COL-5671 in healthy volunteers were presented in February during the European Crohn\u2019s and Colitis Organization meeting in Stockholm. Coultreon reported its drug showed the ability to inhibit TNF\u03b1 \u201cas efficiently as monoclonal antibodies.\u201d For the 15 mg dose, the third highest of four doses evaluated to date in the study, Coultreon reported the drug led to sustained TNF\u03b1 inhibition. At 24 hours, this inhibition remained higher than 90%.<\/p>\n<p>The company said the human data along with the preclinical research show COL-5671 has the potential to treat a variety of autoimmune diseases. In the Tuesday financing announcement, Coultreon said it aims to advance this molecule to Phase 2 testing in psoriasis and ulcerative colitis; proof of concept data are expected next year.<\/p>\n<p>Coultreon acquired COL-5671 and other small molecule assets from Galapagos last year. Per terms of that deal, Galapagos participated in the startup\u2019s seed financing with a \u20ac20 million (about $23.4 million) loan that would convert to equity in the company\u2019s next financing round, according to Galapagos <a href=\"https:\/\/www.sec.gov\/ix?doc=\/Archives\/edgar\/data\/0001421876\/000110465926035163\/glpg-20251231x20f.htm\" target=\"_blank\" rel=\"noopener\">regulatory filings<\/a>.<\/p>\n<p>Sofinnova Investments led Coultreon\u2019s new financing, a Series A round. Forbion and Novo Holdings are the co-leads. Other investors include Galapagos, Regeneron Ventures, Balyasny Asset Management, Luma Group, Samsara BioCapital, Longwood Fund, and Finchley Healthcare Ventures. Coultreon is led by CEO Pierre Raboisson, who previously served as head of discovery and preclinical development at Galapagos.<\/p>\n<p>\u201cThis financing marks a major inflection point for our company,\u201d Raboisson said in a prepared statement. \u201cWith the support of this top-tier syndicate, we are well positioned to advance our SIK program, while unlocking the broader potential of our pipeline.\u201d<\/p>\n<p><em>Photo: megaflopp, Getty Images<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Coultreon Biopharma\u2019s lead drug candidate, acquired from Galapagos, is a small molecule designed to selectively inhibit a novel immunology target called SIK3. The Series A financing will support Phase 2 clinical trials in psoriasis and ulcerative colitis.<\/p>\n","protected":false},"author":25932,"featured_media":17544,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"om_disable_all_campaigns":false,"featured_image_focal_point":[],"homepage_placement":"top","homepage_placements":{"top":true,"featured":true,"sidebar":false},"homepage_alternative_layout":false,"featured_categories":[60,69],"hide_from_feed":false,"footnotes":""},"categories":[69,60],"tags":[42355,12102,53592,11205,40579,10296,7758,9267,8316,11652],"class_list":["post-146774","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-biopharma","category-startup-channel","tag-biopharma-nl","tag-clinical-trials","tag-coultreon-biopharma","tag-galapagos","tag-immunology","tag-inflammation","tag-investing","tag-psoriasis","tag-startups","tag-ulcerative-colitis"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Immunology-Focused Coultreon Adds $125M for Pills That Pack the Punch of Injectable Biologics - MedCity News<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/medcitynews.com\/2026\/04\/immunology-inflammation-startup-coultreon-biopharma-sik-inhibitor-galapagos\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Immunology-Focused Coultreon Adds $125M for Pills That Pack the Punch of Injectable Biologics - MedCity News\" \/>\n<meta property=\"og:description\" content=\"Coultreon Biopharma\u2019s lead drug candidate, acquired from Galapagos, is a small molecule designed to selectively inhibit a novel immunology target called SIK3. The Series A financing will support Phase 2 clinical trials in psoriasis and ulcerative colitis.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/medcitynews.com\/2026\/04\/immunology-inflammation-startup-coultreon-biopharma-sik-inhibitor-galapagos\/\" \/>\n<meta property=\"og:site_name\" content=\"MedCity News\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-28T17:30:01+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-04-29T14:09:09+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/medcitynews.com\/wp-content\/uploads\/sites\/7\/2021\/07\/GettyImages-1291405630-600x400.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"600\" \/>\n\t<meta property=\"og:image:height\" content=\"400\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Frank Vinluan\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@frankvinluan\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Frank Vinluan\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/medcitynews.com\/2026\/04\/immunology-inflammation-startup-coultreon-biopharma-sik-inhibitor-galapagos\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/medcitynews.com\/2026\/04\/immunology-inflammation-startup-coultreon-biopharma-sik-inhibitor-galapagos\/\"},\"author\":{\"name\":\"Frank Vinluan\",\"@id\":\"https:\/\/medcitynews.com\/#\/schema\/person\/327ad000c78d52bed5e2ed77a994ce35\"},\"headline\":\"Immunology-Focused Coultreon Adds $125M for Pills That Pack the Punch of Injectable Biologics\",\"datePublished\":\"2026-04-28T17:30:01+00:00\",\"dateModified\":\"2026-04-29T14:09:09+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/medcitynews.com\/2026\/04\/immunology-inflammation-startup-coultreon-biopharma-sik-inhibitor-galapagos\/\"},\"wordCount\":609,\"commentCount\":0,\"image\":{\"@id\":\"https:\/\/medcitynews.com\/2026\/04\/immunology-inflammation-startup-coultreon-biopharma-sik-inhibitor-galapagos\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/medcitynews.com\/wp-content\/uploads\/sites\/7\/2021\/07\/GettyImages-1291405630.jpg\",\"keywords\":[\"biopharma nl\",\"Clinical Trials\",\"Coultreon Biopharma\",\"Galapagos\",\"immunology\",\"inflammation\",\"investing\",\"psoriasis\",\"Startups\",\"ulcerative colitis\"],\"articleSection\":[\"BioPharma\",\"Startups\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/medcitynews.com\/2026\/04\/immunology-inflammation-startup-coultreon-biopharma-sik-inhibitor-galapagos\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/medcitynews.com\/2026\/04\/immunology-inflammation-startup-coultreon-biopharma-sik-inhibitor-galapagos\/\",\"url\":\"https:\/\/medcitynews.com\/2026\/04\/immunology-inflammation-startup-coultreon-biopharma-sik-inhibitor-galapagos\/\",\"name\":\"Immunology-Focused Coultreon Adds $125M for Pills That Pack the Punch of Injectable Biologics - MedCity News\",\"isPartOf\":{\"@id\":\"https:\/\/medcitynews.com\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/medcitynews.com\/2026\/04\/immunology-inflammation-startup-coultreon-biopharma-sik-inhibitor-galapagos\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/medcitynews.com\/2026\/04\/immunology-inflammation-startup-coultreon-biopharma-sik-inhibitor-galapagos\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/medcitynews.com\/wp-content\/uploads\/sites\/7\/2021\/07\/GettyImages-1291405630.jpg\",\"datePublished\":\"2026-04-28T17:30:01+00:00\",\"dateModified\":\"2026-04-29T14:09:09+00:00\",\"author\":{\"@id\":\"https:\/\/medcitynews.com\/#\/schema\/person\/327ad000c78d52bed5e2ed77a994ce35\"},\"breadcrumb\":{\"@id\":\"https:\/\/medcitynews.com\/2026\/04\/immunology-inflammation-startup-coultreon-biopharma-sik-inhibitor-galapagos\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/medcitynews.com\/2026\/04\/immunology-inflammation-startup-coultreon-biopharma-sik-inhibitor-galapagos\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/medcitynews.com\/2026\/04\/immunology-inflammation-startup-coultreon-biopharma-sik-inhibitor-galapagos\/#primaryimage\",\"url\":\"https:\/\/medcitynews.com\/wp-content\/uploads\/sites\/7\/2021\/07\/GettyImages-1291405630.jpg\",\"contentUrl\":\"https:\/\/medcitynews.com\/wp-content\/uploads\/sites\/7\/2021\/07\/GettyImages-1291405630.jpg\",\"width\":2120,\"height\":1414,\"caption\":\"prescription drug medication\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/medcitynews.com\/2026\/04\/immunology-inflammation-startup-coultreon-biopharma-sik-inhibitor-galapagos\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/medcitynews.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Immunology-Focused Coultreon Adds $125M for Pills That Pack the Punch of Injectable Biologics\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/medcitynews.com\/#website\",\"url\":\"https:\/\/medcitynews.com\/\",\"name\":\"MedCity News\",\"description\":\"Healthcare technology news, life science current events\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/medcitynews.com\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/medcitynews.com\/#\/schema\/person\/327ad000c78d52bed5e2ed77a994ce35\",\"name\":\"Frank Vinluan\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/medcitynews.com\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/medcitynews.com\/wp-content\/uploads\/sites\/7\/2023\/05\/cropped-FrankVinluan_headshot-96x96.jpg\",\"contentUrl\":\"https:\/\/medcitynews.com\/wp-content\/uploads\/sites\/7\/2023\/05\/cropped-FrankVinluan_headshot-96x96.jpg\",\"caption\":\"Frank Vinluan\"},\"description\":\"Frank Vinluan is senior biopharma reporter for MedCity News. He previously held business reporting positions at Xconomy, The Seattle Times, The Des Moines Register, and the Triangle Business Journal. LinkedIn: https:\/\/www.linkedin.com\/in\/frankvinluan\/ Twitter: @frankvinluan\",\"sameAs\":[\"https:\/\/www.linkedin.com\/in\/frankvinluan\/\",\"https:\/\/x.com\/frankvinluan\"],\"url\":\"https:\/\/medcitynews.com\/author\/fvinluan\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Immunology-Focused Coultreon Adds $125M for Pills That Pack the Punch of Injectable Biologics - MedCity News","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/medcitynews.com\/2026\/04\/immunology-inflammation-startup-coultreon-biopharma-sik-inhibitor-galapagos\/","og_locale":"en_US","og_type":"article","og_title":"Immunology-Focused Coultreon Adds $125M for Pills That Pack the Punch of Injectable Biologics - MedCity News","og_description":"Coultreon Biopharma\u2019s lead drug candidate, acquired from Galapagos, is a small molecule designed to selectively inhibit a novel immunology target called SIK3. The Series A financing will support Phase 2 clinical trials in psoriasis and ulcerative colitis.","og_url":"https:\/\/medcitynews.com\/2026\/04\/immunology-inflammation-startup-coultreon-biopharma-sik-inhibitor-galapagos\/","og_site_name":"MedCity News","article_published_time":"2026-04-28T17:30:01+00:00","article_modified_time":"2026-04-29T14:09:09+00:00","og_image":[{"width":600,"height":400,"url":"https:\/\/medcitynews.com\/wp-content\/uploads\/sites\/7\/2021\/07\/GettyImages-1291405630-600x400.jpg","type":"image\/jpeg"}],"author":"Frank Vinluan","twitter_card":"summary_large_image","twitter_creator":"@frankvinluan","twitter_misc":{"Written by":"Frank Vinluan","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/medcitynews.com\/2026\/04\/immunology-inflammation-startup-coultreon-biopharma-sik-inhibitor-galapagos\/#article","isPartOf":{"@id":"https:\/\/medcitynews.com\/2026\/04\/immunology-inflammation-startup-coultreon-biopharma-sik-inhibitor-galapagos\/"},"author":{"name":"Frank Vinluan","@id":"https:\/\/medcitynews.com\/#\/schema\/person\/327ad000c78d52bed5e2ed77a994ce35"},"headline":"Immunology-Focused Coultreon Adds $125M for Pills That Pack the Punch of Injectable Biologics","datePublished":"2026-04-28T17:30:01+00:00","dateModified":"2026-04-29T14:09:09+00:00","mainEntityOfPage":{"@id":"https:\/\/medcitynews.com\/2026\/04\/immunology-inflammation-startup-coultreon-biopharma-sik-inhibitor-galapagos\/"},"wordCount":609,"commentCount":0,"image":{"@id":"https:\/\/medcitynews.com\/2026\/04\/immunology-inflammation-startup-coultreon-biopharma-sik-inhibitor-galapagos\/#primaryimage"},"thumbnailUrl":"https:\/\/medcitynews.com\/wp-content\/uploads\/sites\/7\/2021\/07\/GettyImages-1291405630.jpg","keywords":["biopharma nl","Clinical Trials","Coultreon Biopharma","Galapagos","immunology","inflammation","investing","psoriasis","Startups","ulcerative colitis"],"articleSection":["BioPharma","Startups"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/medcitynews.com\/2026\/04\/immunology-inflammation-startup-coultreon-biopharma-sik-inhibitor-galapagos\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/medcitynews.com\/2026\/04\/immunology-inflammation-startup-coultreon-biopharma-sik-inhibitor-galapagos\/","url":"https:\/\/medcitynews.com\/2026\/04\/immunology-inflammation-startup-coultreon-biopharma-sik-inhibitor-galapagos\/","name":"Immunology-Focused Coultreon Adds $125M for Pills That Pack the Punch of Injectable Biologics - MedCity News","isPartOf":{"@id":"https:\/\/medcitynews.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/medcitynews.com\/2026\/04\/immunology-inflammation-startup-coultreon-biopharma-sik-inhibitor-galapagos\/#primaryimage"},"image":{"@id":"https:\/\/medcitynews.com\/2026\/04\/immunology-inflammation-startup-coultreon-biopharma-sik-inhibitor-galapagos\/#primaryimage"},"thumbnailUrl":"https:\/\/medcitynews.com\/wp-content\/uploads\/sites\/7\/2021\/07\/GettyImages-1291405630.jpg","datePublished":"2026-04-28T17:30:01+00:00","dateModified":"2026-04-29T14:09:09+00:00","author":{"@id":"https:\/\/medcitynews.com\/#\/schema\/person\/327ad000c78d52bed5e2ed77a994ce35"},"breadcrumb":{"@id":"https:\/\/medcitynews.com\/2026\/04\/immunology-inflammation-startup-coultreon-biopharma-sik-inhibitor-galapagos\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/medcitynews.com\/2026\/04\/immunology-inflammation-startup-coultreon-biopharma-sik-inhibitor-galapagos\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/medcitynews.com\/2026\/04\/immunology-inflammation-startup-coultreon-biopharma-sik-inhibitor-galapagos\/#primaryimage","url":"https:\/\/medcitynews.com\/wp-content\/uploads\/sites\/7\/2021\/07\/GettyImages-1291405630.jpg","contentUrl":"https:\/\/medcitynews.com\/wp-content\/uploads\/sites\/7\/2021\/07\/GettyImages-1291405630.jpg","width":2120,"height":1414,"caption":"prescription drug medication"},{"@type":"BreadcrumbList","@id":"https:\/\/medcitynews.com\/2026\/04\/immunology-inflammation-startup-coultreon-biopharma-sik-inhibitor-galapagos\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/medcitynews.com\/"},{"@type":"ListItem","position":2,"name":"Immunology-Focused Coultreon Adds $125M for Pills That Pack the Punch of Injectable Biologics"}]},{"@type":"WebSite","@id":"https:\/\/medcitynews.com\/#website","url":"https:\/\/medcitynews.com\/","name":"MedCity News","description":"Healthcare technology news, life science current events","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/medcitynews.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/medcitynews.com\/#\/schema\/person\/327ad000c78d52bed5e2ed77a994ce35","name":"Frank Vinluan","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/medcitynews.com\/#\/schema\/person\/image\/","url":"https:\/\/medcitynews.com\/wp-content\/uploads\/sites\/7\/2023\/05\/cropped-FrankVinluan_headshot-96x96.jpg","contentUrl":"https:\/\/medcitynews.com\/wp-content\/uploads\/sites\/7\/2023\/05\/cropped-FrankVinluan_headshot-96x96.jpg","caption":"Frank Vinluan"},"description":"Frank Vinluan is senior biopharma reporter for MedCity News. He previously held business reporting positions at Xconomy, The Seattle Times, The Des Moines Register, and the Triangle Business Journal. LinkedIn: https:\/\/www.linkedin.com\/in\/frankvinluan\/ Twitter: @frankvinluan","sameAs":["https:\/\/www.linkedin.com\/in\/frankvinluan\/","https:\/\/x.com\/frankvinluan"],"url":"https:\/\/medcitynews.com\/author\/fvinluan\/"}]}},"_links":{"self":[{"href":"https:\/\/medcitynews.com\/wp-json\/wp\/v2\/posts\/146774","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medcitynews.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medcitynews.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medcitynews.com\/wp-json\/wp\/v2\/users\/25932"}],"replies":[{"embeddable":true,"href":"https:\/\/medcitynews.com\/wp-json\/wp\/v2\/comments?post=146774"}],"version-history":[{"count":5,"href":"https:\/\/medcitynews.com\/wp-json\/wp\/v2\/posts\/146774\/revisions"}],"predecessor-version":[{"id":146793,"href":"https:\/\/medcitynews.com\/wp-json\/wp\/v2\/posts\/146774\/revisions\/146793"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medcitynews.com\/wp-json\/wp\/v2\/media\/17544"}],"wp:attachment":[{"href":"https:\/\/medcitynews.com\/wp-json\/wp\/v2\/media?parent=146774"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medcitynews.com\/wp-json\/wp\/v2\/categories?post=146774"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medcitynews.com\/wp-json\/wp\/v2\/tags?post=146774"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}